Measles virus glycoprotein-pseudotyped lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic modification of monocyte-derived dendritic cells

Journal of Virology

Volumn 86, Issue 9, 2012, Pages 5192-5203

  Humbert, J M ^a,b,c   Frecha, C ^a,d,e   Bouafi, F Amirache ^a,d,e   N'Guyen, T H ^a,b,c   Boni, S ^a,b,c   Cosset, F L ^a,d,e   Verhoeyen, E ^a,d,e   Halary, F ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; CD209 ANTIGEN; ENVELOPE PROTEIN; LENTIVIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; PROTEIN VPX; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VPR PROTEIN;

ARTICLE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CYTOLOGY; DENDRITIC CELL; DNA MODIFICATION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MEASLES VIRUS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VESICULAR STOMATITIS VIRUS; VESICULAR STOMATITIS VIRUS G; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS PARTICLE; VIRUS TYPING;

ANTIGENS, CD46; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; DENDRITIC CELLS; G0 PHASE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LECTINS, C-TYPE; LENTIVIRUS; MEASLES VIRUS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 3; TRANSDUCTION, GENETIC; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS;

MEASLES VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84860298517     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06283-11     Document Type: Article

References (90)

1. Alvarez CP, et al. 2002. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76:6841-6844.
2. Ardeshna KM, et al. 2000. Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br. J. Haematol. 108:817-824.
3. Arrighi JF, et al. 2004. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J. Exp. Med. 200:1279-1288.
4. Aversa G, et al. 1997. SLAM and its role in T cell activation and Th cell responses. Immunol. Cell Biol. 75:202-205.
5. Avota E, Gulbins E, Schneider-Schaulies S. 2011. DC-SIGN mediated sphingomyelinase-activation and ceramide generation is essential for enhancement of viral uptake in dendritic cells. PLoS Pathog. 7:e1001290.
6. Banchereau J, et al. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811.
7. Banchereau J, Palucka AK. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5:296-306.
8. Berger G, et al. 2011. A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat. Protoc. 6:806-816.
9. Breckpot K, Aerts JL, Thielemans K. 2007. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther. 14:847-862.
10. Breckpot K, et al. 2007. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum. Gene Ther. 18:536-546.
11. Breckpot K, Heirman C, Neyns B, Thielemans K. 2004. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J. Gene Med. 6:1175-1188.
12. Cavalieri S, et al. 2003. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102:497-505.
13. Cheng WF, et al. 2006. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. Cancer Gene Ther. 13:873-885.
14. Clanchy FI, Holloway AC, Lari R, Cameron PU, Hamilton JA. 2006. Detection and properties of the human proliferative monocyte subpopulation. J. Leukoc. Biol. 79:757-766.
15. Cocks BG, et al. 1995. A novel receptor involved in T-cell activation. Nature 376:260-263.
16. Davis ID, Jefford M, Parente P, Cebon J. 2003. Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 73:3-29.
17. de Witte L, Abt M, Schneider-Schaulies S, van Kooyk Y, Geijtenbeek TB. 2006. Measles virus targets DC-SIGN to enhance dendritic cell infection. J. Virol. 80:3477-3486.
18. de Witte L, et al. 2008. DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes. PLoS Pathog. 4:e1000049.
19. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193:233-238.
20. Dorig RE, Marcil A, Chopra A, Richardson CD. 1993. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75:295-305.
21. + T cell responses. J. Clin. Invest. 111:1673-1681.
22. Esslinger C, Romero P, MacDonald HR. 2002. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum. Gene Ther. 13:1091-1100.
23. Feinberg H, Mitchell DA, Drickamer K, Weis WI. 2001. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294:2163-2166.
24. Finnin M, Hamilton JA, Moss ST. 1999. Characterization of a CSFinduced proliferating subpopulation of human peripheral blood monocytes by surface marker expression and cytokine production. J. Leukoc. Biol. 66:953-960.
25. Firat H, et al. 2002. Use of a lentiviral flap vector for induction of CTL immunity against melanoma: perspectives for immunotherapy. J. Gene Med. 4:38-45.
26. Frecha C, et al. 2009. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 114:3173-3180.
27. Frecha C, et al. 2008. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112:4843-4852.
28. + cells in a humanized mouse model. Methods Mol. Biol. 737:367-390.
29. Frecha C, Levy C, Cosset FL, Verhoeyen E. 2010. Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol. Ther. 18:1748-1757.
30. Frecha C, et al. 2011. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J. Virol. 85:5975-5985.
31. Froelich S, Tai A, Kennedy K, Zubair A, Wang P. 2011. Pseudotyping lentiviral vectors with aura virus envelope glycoproteins for DC-SIGNmediated transduction of dendritic cells. Hum. Gene Ther. 10:1281-1291.
32. Froelich S, Tai A, Kennedy K, Zubair A, Wang P. 2011. Virus-receptor mediated transduction of dendritic cells by lentiviruses enveloped with glycoproteins derived from Semliki forest virus. PLoS One 6:e21491.
33. Fujita M, et al. 2008. Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages. J. Virol. 82: 7752-7756.
34. Funke S, et al. 2008. Targeted cell entry of lentiviral vectors. Mol. Ther. 16:1427-1436.
35. Funke S, et al. 2009. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther. 16: 700-705.
36. Geijtenbeek TB, den Dunnen J, Gringhuis SI. 2009. Pathogen recognition by DC-SIGN shapes adaptive immunity. Future Microbiol. 4:879-890.
37. Geijtenbeek TB, et al. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597.
38. Geijtenbeek TB, et al. 2000. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100:575-585.
39. Gilboa E, Nair SK, Lyerly HK. 1998. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46:82-87.
40. Goujon C, et al. 2008. Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J. Virol. 82:12335-12345.
41. Goujon C, et al. 2003. Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells. J. Virol. 77:9295-9304.
42. Goujon C, et al. 2006. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther. 13:991-994.
43. Goujon C, et al. 2007. SIVSM/HIV-2 Vpx proteins promote retroviralescape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 4:2.
44. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Geijtenbeek TB. 2009. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1, and Helicobacter pylori. Nat. Immunol. 10:1081-1088.
45. kB. Immunity 26:605-616.
46. Halary F, et al. 2002. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity 17:653-664.
47. Hrecka K, et al. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474:658-661.
48. Jain P, et al. 2009. DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells. J. Virol. 83:10908-10921.
49. + T cell responses. Vaccine 28:922-933.
50. Kaplan JM, et al. 1999. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumorassociated antigens. J. Immunol. 163:699-707.
51. Kaushik R, Zhu X, Stranska R, Wu Y, Stevenson M. 2009. A cellular restriction dictates the permissivity of nondividing monocytes/ macrophages to lentivirus and gammaretrovirus infection. Cell Host Microbe 6:68-80.
52. Korin YD, Zack JA. 1998. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72:3161-3168.
53. + dendritic cells and is up-regulated by IL-1β. J. Immunol. 167:1989-1995.
54. Laguette N, et al. 2011. SAMHD1 is the dendritic- and myeloid-cellspecific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-657.
55. Lari R, Kitchener PD, Hamilton JA. 2009. The proliferative human monocyte subpopulation contains osteoclast precursors. Arthritis Res. Ther. 11:R23.
56. Leonard VH, et al. 2008. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J. Clin. Invest. 118:2448-2458.
57. Levy C, et al. 2010. Lentiviral vectors and transduction of human cancer B cells. Blood 116:498-500.
58. Lu W, Arraes LC, Ferreira WT, Andrieu JM. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
59. Manel N, et al. 2010. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467:214-217.
60. Mangeot PE, et al. 2000. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J. Virol. 74:8307-8315.
61. Maurice M, et al. 2002. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cellactivating polypeptide. Blood 99:2342-2350.
62. Mitchell DA, Fadden AJ, Drickamer K. 2001. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR: subunit organization and binding to multivalent ligands. J. Biol. Chem. 276:28939-28945.
63. Morizono K, et al. 2010. Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J. Virol. 84:6923-6934.
64. Naniche D, et al. 1993. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67:6025-6032.
65. Navarro-Sanchez E, et al. 2003. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 4:723-728.
66. Negre D, et al. 2000. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther. 7:1613-1623.
67. Pohlmann S, et al. 2001. DC-SIGN interactions with human immunodeficiency virus: virus binding and transfer are dissociable functions. J. Virol. 75:10523-10526.
68. Puri A, et al. 1988. Activation of vesicular stomatitis virus fusion with cells by pretreatment at low pH. J. Biol. Chem. 263:4749-4753.
69. Rea D, et al. 2001. Highly efficient transduction of human monocytederived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166:5236-5244.
70. Relloso M, et al. xpression is IL-4 dependent and is negatively regulated by IFN, TGF-β, and anti-inflammatory agents. J. Immunol. 168:2634-2643.
71. Ribas A, Butterfield LH, Glaspy JA, Economou JS. 2002. Cancer immunotherapy using gene-modified dendritic cells. Curr. Gene Ther. 2:57-78.
72. Roche S, Albertini AA, Lepault J, Bressanelli S, Gaudin Y. 2008. Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited. Cell Mol. Life Sci. 65:1716-1728.
73. Sallusto F, Lanzavecchia A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
74. Schule S, et al. 2009. Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj. PLoS One 4:e7098.
75. Senju S, et al. 2011. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther.
76. Soilleux EJ, Morris LS, Trowsdale J, Coleman N, Boyle JJ. 2002. Human atherosclerotic plaques express DC-SIGN, a novel protein found on dendritic cells and macrophages. J. Pathol. 198:511-516.
77. Song W, Tong Y, Carpenter H, Kong HL, Crystal RG. 2000. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen. Gene Ther. 7:2080-2086.
78. Srivastava S, et al. 2008. Lentiviral Vpx accessory factor targets VprBP/ DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog. 4:e1000059.
79. Steinman RM, Hawiger D, Nussenzweig MC. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685-711.
80. Su Z, Frye C, Bae KM, Kelley V, Vieweg J. 2008. Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions. Clin. Cancer Res. 14:6207-6217.
81. Tahara M, et al. 2008. Measles virus infects both polarized epithelial and immune cells by using distinctive receptor-binding sites on its hemagglutinin. J. Virol. 82:4630-4637.
82. Tan PH, et al. 2005. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 105:3824-3832.
83. Tatsuo H, Ono N, Tanaka K, Yanagi Y. 2000. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406:893-897.
84. + cord blood-derived dendritic cells. Gene Ther. 9:1551-1560.
85. Unutmaz D, KewalRamani VN, Marmon S, Littman DR. 1999. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189:1735-1746.
86. Verhoeyen E, et al. 2003. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 101:2167-2174.
87. Yanagi Y, Ono N, Tatsuo H, Hashimoto K, Minagawa H. 2002. Measles virus receptor SLAM (CD150). Virology 299:155-161.
88. Yanagi Y, Takeda M, Ohno S. 2006. Measles virus: cellular receptors, tropism and pathogenesis. J. Gen. Virol. 87:2767-2779.
89. Yang L, et al. 2008. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26:326-334.
90. Yao Y, Ghosh K, Epand RF, Epand RM, Ghosh HP. 2003. Membrane fusion activity of vesicular stomatitis virus glycoprotein G is induced by low pH but not by heat or denaturant. Virology 310:319-332.